Trial Profile

An Open Label, Phase IIIb, Randomised Parallel Group Study to Assess the Efficacy and Safety of Switching HIV-1 Infected Patients Successfully Treated With a Nevirapine IR Based Regimen to Nevirapine XR 400 mg QD or Remaining on Nevirapine IR 200 mg BID Based Program

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 15 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nevirapine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir; Lamivudine/zidovudine; Nevirapine
Indications HIV-1 infections
Focus Registrational; Therapeutic Use
Acronyms TRANxITION
Sponsors Boehringer Ingelheim Pharmaceuticals

01 Apr 2012 Results published in HIV Medicine.
23 Feb 2012 Actual number of patients changed from 443 to 445 as reported by ClinicalTrials.gov.
23 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com